In a phase II clinical trial in NASH patients (n = 289), the dual CCR2/CCR5 inhibitor cenicriviroc has demonstrated anti-fibrotic efficacy after one year of treatment [18]. Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.